Context Therapeutics

About:

Context Therapeutics is a clinical-stage biopharmaceutical company.

Website: http://www.contexttherapeutics.com/

Twitter/X: context_tx

Top Investors: Blue Owl, Deep Track Capital, Great Point Partners, Avidity Partners, Torrey Pines Investment

Description:

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.